PBAC's latest decision on Durvalumab, olaparib: Recommended with restriction (2024). Considered for Advanced, metastatic or recurrent endometrial cancer (dMMR population receiving durvalumab + platinum-based chemotherapy followed by maintenance durvalumab monotherapy; pMMR population receiving durvalumab + platinum-based chemotherapy followed by durvalumab + olaparib maintenance).
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adults with advanced, metastatic or recurrent endometrial cancer (either dMMR or pMMR) who have not received prior systemic therapy or whose disease progressed following adjuvant systemic therapy, with ECOG performance status 0-1, unsuitable for curative surgery or radiotherapy, and without prior PD-1/PD-L1 inhibitor treatment.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
DUO-E
Comparator
dMMR: dostarlimab + PC; pMMR: PC alone
Economic model
CUA
ICER note
For dMMR population, cost-minimisation analysis was used (no ICER). For pMMR population, the ICER is not explicitly stated in this public summary document.